ACT Poster Presentations Group 2

Poster Session Moderator(s)

• JE

  Jesus Esquivel, MD

  Co-director Peritoneal Surface Malignancy Program
  Beebe Healthcare
  Lewes, Delaware, United States

Presentations:

• 12:00 PM – 12:05 PM CST

  AP17 Review of safety data for Adenovirus 5 (Ad5) as a delivery vector for intratumoral cancer gene therapy
  

  Poster Presenter: Yarrow Sheldon, MD – Christiana Care
• 12:05 PM – 12:10 PM CST

  AP9 Opioid and Psychotropic Medication Use in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Patients
  

  Poster Presenter: Ian Solsky, MD, MPH – Wake Forest
• 12:10 PM – 12:15 PM CST

  AP10 Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for hereditary colorectal cancer syndrome patients with peritoneal metastases
  

  Poster Presenter: Melanie Ongchin, MD – University of Pittsburgh Medical Center
• 12:15 PM – 12:20 PM CST

  AP11 Survival in Total Pre-Operative vs. Peri-Operative Chemotherapy for Patients with Metastatic High-Grade Appendiceal Adenocarcinoma Undergoing CRS/HIPEC
  

  Poster Presenter: Ryan B. Morgan, MD – University of Chicago Medicine
• 12:20 PM – 12:25 PM CST

  AP18 Safety and efficacy of pressurized intraperitoneal aerosolized chemotherapy in appendiceal and colorectal cancer patients with peritoneal carcinomatosis: A first-in-US phase I study
  

  Poster Presenter: Mustafa Raoof, MD, FACS – Department of Surgery, Cancer Genetics and Epigenetics
• 12:25 PM – 12:30 PM CST

  AP5 Controlling Perfusion Temperature Relates to Better Outcomes after CRS/HIPEC
  

  Poster Presenter: Felipe Lopez-Ramirez, MD – Mercy Medical Center
• 12:35 PM – 12:40 PM CST

  AP6 Cytoreductive Surgery for Metastatic Colorectal Cancer in the Era of Modern Systemic Therapy – a Shifting Paradigm!
  

  Poster Presenter: Stephanie Young, MD MPH – Saint John's Cancer Institute
• 12:40 PM – 12:45 PM CST

  AP7 Early postoperative CRP levels predicts major complications following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
  

  Poster Presenter: Akash Kartik, MBBS – Mayo Clinic, Arizona
• 12:45 PM – 12:50 PM CST

  AP8 Limited lung metastases do not alter outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal disease
  

  Poster Presenter: Shachar Laks, MD FACS – Sheba Medical Center Affiliated with Tel Aviv University